New funding from Vodafone Ventures Ltd will enable t+ Medical, the UK-based company that supplies mobile phone-based technology for capturing patient data in long-term condition management and clinical trials, to accelerate the roll-out of its mPRO (mobile patient reported outcomes) platform.

The undisclosed investment from Vodafone Ventures, the corporate venture capital arm of Vodafone Group, will support a platform specifically designed to facilitate patient data collection in clinical studies. Last year t+ Medical set up a dedicated subsidiary, t+ Clinical, to market data-capture solutions for late-stage clinical trials to pharmaceutical clients.

Among the benefits of the mPRO platform, t+ Medical said, are reduced timelines between drug discovery and launch; improved protection for trial participants by eliminating inaccuracies that arise when patients do not complete their paper diaries; helping pharmaceutical companies to shift towards a technological system of patient data capture as recommended by the US Food and Drug Administration; real-time analysis of clinical data, enabling early adaptations of trials; and high levels of user compliance due to familiar mobile phone hardware.

With the mPRO system, trial participants enter data into an interactive diary programme on their mobile. Using secure mobile networks, the information is then downloaded automatically and immediately to t+ servers for analysis.